Related Experiment Video
Updated: Apr 9, 2026
Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
HERV-W association with serum biomarkers NfL and GFAP in multiple sclerosis
Stefano Ruberto1, Maria I Dominguez-Mozo1, Luisa María Villar2
1Grupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Red de Enfermedades Inflamatorias (REI), Red Española de Esclerosis Múltiple, Madrid, Spain.
Background:
Serum biomarkers of multiple sclerosis (MS), such as glial fibrillary acidic protein (sGFAP) and neurofilament light chain (sNfL), are established indicators of disease progression and disability. Human endogenous retrovirus of the W family (HERV-W) is repeatedly associated with MS neuroinflammation, but its relationship with neural injury biomarkers is unclear.
Methods:
We measured anti-pHERV-W, -syncytin-1 IgG and their Ratio (HERV-W) in 83 RR-MS patients and 112 healthy controls (HC). Age and sex-adjusted sNfL/sGFAP Z-scores were derived from HC-calibrated GAMLSS models. HERV-W humoral responses were correlated with MS severity score (MSSS), cytokines (Olink™), and clinical phases (acute MS [AMS], stable MS [SMS]) via non-parametric tests and discriminant analysis.
Results:
HERV-W showed no difference between MS patients and HC, consistent with stable low-EDSS RR-MS predominance. HERV-W ratio correlated positively with Z-sNfL (ρ=0.67, p=0.012), Z-sGFAP (ρ=0.54, p=0.048), MSSS, and proinflammatory cytokines (IL-6, IL-1β and CXCL-9/10) specifically in AMS and SMS-EDSS>4 subgroups. AMS patients with elevated sNfL (>10 pg/ml; Z-score >1.5) exhibited markedly higher HERV-W than those with lower sNfl values. Discriminant models combining HERV-W, sNfL, and sGFAP achieved 82% of accuracy for MS-EDSS>4 classification; excluding HERV-W reduced the correct MS-EDSS>4 classification by 9.1%.
Conclusions:
HERV-W humoral activity shows state-specific associations with sNfL and sGFAP and proinflammatory status in acute and high-disability MS phases. These findings support integrating HERV-W humoral response into dynamic biomarker panels to better stratify patients by inflammatory burden and disability trajectory, positioning it as a cofactor linking immune dysregulation to neurodegeneration rather than a singular MS marker.
